Skip to Content
Søk Menu
Velkommen til lungekreft

Få de nyeste artiklene og MEDtalks om lungekreft

Siste nytt om lungekreft

Lung Cancer Insights: What’s New in the Field

  • / Jan Andreasen / Amanda Feldballe Bernholm
Pasi Jänne

New Class of Medicines Emerge as Potential Therapies in MTAP-Deleted NSCLC

/ Pasi Jänne
LungekreftNSCLCWCLC25 Play the Video
Michael Stenger

WCLC 2025: Lung Cancer Screening and Early Results from the Danish PLUS Trial

/ Michael Stenger
LungekreftWCLC25 Play the Video

New Data Support Osimertinib as a Backbone Treatment for EGFRm Advanced NSCLC

/ Jan Andreasen
LungekreftNSCLCWCLC25

Lung cancer highlights

Amivantamab + Lazertinib in EGFR-Mutated Advanced NSCLC: PALOMA-2 Update

/ Jan Andreasen
LungekreftNSCLCWCLC25

First-Line NSCLC Without Driver Mutations: Practice, Gaps, and Costs

/ Ronny Öhman / Jan Andreasen
LungekreftNSCLC

Lazertinib + Amivantamab: A New Chemotherapy-Free Option for EGFR-Mutated Advanced NSCLC

/ Antonio Passaro / Jan Andreasen
Lungekreft
Load more

Artikler

New Treatment Possibilities Improve Future Outcomes of Lung Cancer

/ BestPractice Nordic
ESMO24Lungekreft

No Major Breakthroughs in Lung Cancer Compared to ESMO 2023

/ BestPractice Nordic
ESMO24Lungekreft

WCLC 2023 – NSCLC: New Data on Perioperative Immunotherapy Treatment 

/ BestPractice Nordic
ImmunterapiLungekreftNSCLCWCLC23

Adjuvant treatment with 3rd generation EGFR-TKI can increase progression-free survival 

/ BestPractice Nordic
LungekreftNSCLCWCLC23

CheckMate 227: 6-year data on the treatment of locally advanced NSCLC with Opdivo and Yervoy  

/ BestPractice Nordic
LungekreftNSCLCWCLC23

Adjuvant Osimertinib – New Standard of Care for Patients with Resected EGFR-mutated NSCLC

/ BestPractice Nordic
ASCO23Lungekreft

WCLC | Kongress

6.-9. september 2025

Se alt innhold her

MEDtalks

Maria Silvoniemi

Clinical Dilemmas in the Management of NSCLC Without Driver Mutations

/ Maria Silvoniemi
LungekreftNSCLC Play the Video
Bjørn H Grønberg

Perioperativ behandling ved ikke-småcellet lungekreft

/ Bjørn Henning Grønberg
Lungekreft Play the Video
Luis Paz-Ares

ASCO 2025: Lurbinectedin–Atezolizumab Improves Survival in SCLC

/ Luis Paz-Ares
ASCO25Lungekreft Play the Video
Odd Terje Brustugun

Perspektiver på behandlingsvalg ved NSCLC uten drivermutasjoner

/ Odd Terje Brustugun
Lungekreft Play the Video
Bjørn H Grønberg

Kombinasjonsbehandling for EGFR-mutert lungekreft viser økt overlevelse

/ Bjørn Henning Grønberg
Lungekreft Play the Video
Miriam Grønberg

Treatment Timing Impacts Survival in Limited Stage Small Cell Lung Cancer

/ Miriam Grønberg
Lungekreft Play the Video
Load more

Back to top